Overview

First-in-Human Single Ascending Dose of GLPG0492

Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) oral dose of GLPG0492 compared to placebo in healthy subjects. Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0492 after single oral administration will be evaluated, and, if applicable, the maximum tolerated dose determined. Oral bioavailability (solution vs solid capsule fasting or fed) is evaluated in healthy elderly subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Galapagos NV
Treatments:
Pharmaceutical Solutions